Clinical trial
A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT00522938 is registered in ClinicalTrials.gov with Chroma Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Lead sponsor
- Chroma Therapeutics
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- December 31, 2007
- Completion date
- April 30, 2008
- Enrollment
- 2 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.